{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:28:28Z","timestamp":1791224908241,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with Huntington\u2019s disease (HD), an autosomal-dominant neurodegenerative disease, show substantial variability in age-of-onset, symptom severity and course of illness, warranting the need for biomarkers to anticipate and monitor these features. The HD gene encodes the disease protein huntingtin (Htt), a potentially useful biomarker for this disease. In the current study, we determined whether total Htt protein (normal plus mutant; \u201ctHtt\u201d) could be reliably measured in human saliva, a body fluid that is much more accessible compared to cerebral spinal fluid or even blood, and whether salivary levels of tHtt were clinically meaningful. We collected 146 saliva samples from manifest HD patients, early-premanifest individuals, late-premanifest patients, gene-negative family members and normal controls. We found that tHtt protein could be reliably and stably detected in human saliva and that tHtt levels were significantly increased in saliva from HD individuals compared to normal controls. Salivary tHtt showed no gender effects, nor were levels correlated with total protein levels in saliva. Salivary tHtt was significantly positively correlated with age, but not age-of-onset or CAG-repeat length. Importantly, salivary tHtt was significantly correlated with several clinical measures, indicating relevance to disease symptom onset and\/or severity. Measurements of salivary tHtt offer significant promise as a relevant, non-invasive disease biomarker for HD, and its use could be implemented into clinical applications.<\/jats:p>","DOI":"10.1038\/s41598-018-25095-3","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T11:21:10Z","timestamp":1525346470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Salivary levels of total huntingtin are elevated in Huntington\u2019s disease patients"],"prefix":"10.1038","volume":"8","author":[{"given":"Jody","family":"Corey-Bloom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameera S.","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungmee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay S.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"key":"25095_CR1","doi-asserted-by":"crossref","unstructured":"Huntington\u2019s Disease Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell. 72, 971\u201383 (1993).","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"25095_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/306234a0","volume":"306","author":"JF Gusella","year":"1983","unstructured":"Gusella, J. F. et al. A polymorphic DNA marker genetically linked to Huntington\u2019s disease. Nature. 306, 234\u20138 (1983).","journal-title":"Nature."},{"key":"25095_CR3","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1073\/pnas.0308679101","volume":"101","author":"NS Wexler","year":"2004","unstructured":"Wexler, N. S. et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington\u2019s disease age of onset. Proc Natl Acad Sci USA 101, 3498\u2013503 (2004).","journal-title":"Proc Natl Acad Sci USA"},{"key":"25095_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1469-1809.2006.00335.x","volume":"71","author":"JM Andresen","year":"2007","unstructured":"Andresen, J. M. et al. The relationship between CAG repeat length and age of onset differs for Huntington\u2019s disease patients with juvenile onset or adult onset. Ann Hum Genet. 71, 295\u2013301 (2007).","journal-title":"Ann Hum Genet."},{"key":"25095_CR5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/ng0893-398","volume":"4","author":"SE Andrew","year":"1993","unstructured":"Andrew, S. E. et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington\u2019s disease. Nat Genet. 4, 398\u2013403 (1993).","journal-title":"Nat Genet."},{"key":"25095_CR6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JHD-130082","volume":"2","author":"C Marques Sousa","year":"2013","unstructured":"Marques Sousa, C. & Humbert, S. Huntingtin: here, there, everywhere! J Huntingtons Dis. 2, 395\u2013403 (2013).","journal-title":"J Huntingtons Dis."},{"key":"25095_CR7","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1523\/JNEUROSCI.0146-10.2010","volume":"30","author":"J Miller","year":"2010","unstructured":"Miller, J. et al. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into Huntington\u2019s disease molecular pathogenesis. J. Neurosci. 30, 10541\u201310550 (2010).","journal-title":"J. Neurosci."},{"key":"25095_CR8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","volume":"81","author":"J Nasir","year":"1995","unstructured":"Nasir, J. et al. Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 81, 811\u201323 (1995).","journal-title":"Cell."},{"key":"25095_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.7618107","volume":"269","author":"MP Duyao","year":"1995","unstructured":"Duyao, M. P. et al. Inactivation of the mouse Huntington\u2019s disease gene homolog Hdh. Science. 269, 407\u201310 (1995).","journal-title":"Science."},{"key":"25095_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/ng1095-155","volume":"11","author":"S Zeitlin","year":"1995","unstructured":"Zeitlin, S., Liu, J. P., Chapman, D. L., Papaioannou, V. E. & Efstratiadis, A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington\u2019s disease gene homologue. Nat Genet. 11, 155\u201363 (1995).","journal-title":"Nat Genet."},{"key":"25095_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.expneurol.2011.12.013","volume":"238","author":"M Arrasate","year":"2012","unstructured":"Arrasate, M. & Finkbeiner, S. Protein aggregates in Huntington\u2019s disease. Exp Neurol. 238, 1\u201311 (2012).","journal-title":"Exp Neurol."},{"key":"25095_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/hmg\/8.5.813","volume":"8","author":"K Sathasivam","year":"1999","unstructured":"Sathasivam, K. et al. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet. 8, 813\u201322 (1999).","journal-title":"Hum Mol Genet."},{"key":"25095_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","volume":"8","author":"JM van der Burg","year":"2009","unstructured":"van der Burg, J. M., Bjorkqvist, M. & Brundin, P. Beyond the brain: widespread pathology in Huntington\u2019s disease. Lancet Neurol. 8, 765\u201374 (2009).","journal-title":"Lancet Neurol."},{"key":"25095_CR14","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild, E. J. et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J Clin Invest. 125, 1979\u201386 (2015).","journal-title":"J Clin Invest."},{"key":"25095_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/srep12166","volume":"5","author":"AL Southwell","year":"2015","unstructured":"Southwell, A. L. et al. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci Rep. 5, 12166 (2015).","journal-title":"Sci Rep."},{"key":"25095_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2091-14-34","volume":"14","author":"L Massai","year":"2013","unstructured":"Massai, L. et al. Development of an ELISA assay for the quantification of soluble huntingtin in human blood cells. BMC Biochem. 14, 34 (2013).","journal-title":"BMC Biochem."},{"key":"25095_CR17","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1172\/JCI64565","volume":"122","author":"A Weiss","year":"2012","unstructured":"Weiss, A. et al. Mutant huntingtin fragmentation in immune cells tracks Huntington\u2019s disease progression. J Clin Invest. 122, 3731\u20136 (2012).","journal-title":"J Clin Invest."},{"key":"25095_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1749-6632.1993.tb18338.x","volume":"694","author":"BJ Baum","year":"1993","unstructured":"Baum, B. J. Principles of saliva secretion. Ann N Y Acad Sci. 694, 17\u201323 (1993).","journal-title":"Ann N Y Acad Sci."},{"key":"25095_CR19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3233\/JAD-160748","volume":"55","author":"M Lee","year":"2017","unstructured":"Lee, M., Guo, J. P., Kennedy, K., McGeer, E. G. & McGeer, P. L. A Method for Diagnosing Alzheimer\u2019s Disease Based on Salivary Amyloid-beta Protein 42 Levels. J Alzheimers Dis. 55, 1175\u20131182 (2017).","journal-title":"J Alzheimers Dis."},{"key":"25095_CR20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3233\/JAD-2011-110731","volume":"27","author":"M Shi","year":"2011","unstructured":"Shi, M. et al. Salivary tau species are potential biomarkers of Alzheimer\u2019s disease. J Alzheimers Dis. 27, 299\u2013305 (2011).","journal-title":"J Alzheimers Dis."},{"key":"25095_CR21","doi-asserted-by":"publisher","first-page":"e0151156","DOI":"10.1371\/journal.pone.0151156","volume":"11","author":"G Vivacqua","year":"2016","unstructured":"Vivacqua, G. et al. Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson\u2019s Disease. PLoS One. 11, e0151156 (2016).","journal-title":"PLoS One."},{"key":"25095_CR22","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1093\/brain\/awr015","volume":"134","author":"I Devic","year":"2011","unstructured":"Devic, I. et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson\u2019s disease. Brain. 134, e178 (2011).","journal-title":"Brain."},{"key":"25095_CR23","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.parkreldis.2015.07.021","volume":"21","author":"JM Masters","year":"2015","unstructured":"Masters, J. M., Noyce, A. J., Warner, T. T., Giovannoni, G. & Proctor, G. B. Elevated salivary protein in Parkinson\u2019s disease and salivary DJ-1 as a potential marker of disease severity. Parkinsonism Relat Disord. 21, 1251\u20135 (2015).","journal-title":"Parkinsonism Relat Disord."},{"key":"25095_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1136\/adc.58.6.454","volume":"58","author":"DA Price","year":"1983","unstructured":"Price, D. A., Close, G. C. & Fielding, B. A. Age of appearance of circadian rhythm in salivary cortisol values in infancy. Arch Dis Child. 58, 454\u20136 (1983).","journal-title":"Arch Dis Child."},{"key":"25095_CR25","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1177\/0022034510380414","volume":"89","author":"JA Loo","year":"2010","unstructured":"Loo, J. A., Yan, W., Ramachandran, P. & Wong, D. T. Comparative human salivary and plasma proteomes. J Dent Res. 89, 1016\u201323 (2010).","journal-title":"J Dent Res."},{"key":"25095_CR26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/ana.24406","volume":"78","author":"J Drouin-Ouellet","year":"2015","unstructured":"Drouin-Ouellet, J. et al. Cerebrovascular and blood-brain barrier impairments in Huntington\u2019s disease: Potential implications for its pathophysiology. Ann Neurol. 78, 160\u201377 (2015).","journal-title":"Ann Neurol."},{"key":"25095_CR27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3233\/JHD-130079","volume":"2","author":"W Liu","year":"2013","unstructured":"Liu, W. et al. Increased Steady-State Mutant Huntingtin mRNA in Huntington\u2019s Disease Brain. J Huntingtons Dis. 2, 491\u2013500 (2013).","journal-title":"J Huntingtons Dis."},{"key":"25095_CR28","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/0896-6273(95)90106-X","volume":"15","author":"N Aronin","year":"1995","unstructured":"Aronin, N. et al. CAG expansion affects the expression of mutant Huntingtin in the Huntington\u2019s disease brain. Neuron. 15, 1193\u2013201 (1995).","journal-title":"Neuron."},{"key":"25095_CR29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ana.410420411","volume":"42","author":"E Sapp","year":"1997","unstructured":"Sapp, E. et al. Huntingtin localization in brains of normal and Huntington\u2019s disease patients. Ann Neurol. 42, 604\u201312 (1997).","journal-title":"Ann Neurol."},{"key":"25095_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1100\/tsw.2008.60","volume":"8","author":"S Finkbeiner","year":"2008","unstructured":"Finkbeiner, S. & Mitra, S. The ubiquitin-proteasome pathway in Huntington\u2019s disease. ScientificWorldJournal. 8, 421\u201333 (2008).","journal-title":"ScientificWorldJournal."},{"key":"25095_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fnmol.2016.00027","volume":"9","author":"T Zhao","year":"2016","unstructured":"Zhao, T., Hong, Y., Li, X. J. & Li, S. H. Subcellular Clearance and Accumulation of Huntington Disease Protein: A Mini-Review. Front Mol Neurosci. 9, 27 (2016).","journal-title":"Front Mol Neurosci."},{"issue":"24","key":"25095_CR32","doi-asserted-by":"publisher","first-page":"5280","DOI":"10.1093\/hmg\/dds379","volume":"21","author":"H Jia","year":"2012","unstructured":"Jia, H., Kast, R. J., Steffan, J. S. & Thomas, E. A. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington\u2019s disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum Mol Genet. 21(24), 5280\u20135293 (2012).","journal-title":"Hum Mol Genet."},{"key":"25095_CR33","doi-asserted-by":"publisher","first-page":"7454","DOI":"10.1523\/JNEUROSCI.6379-11.2012","volume":"32","author":"J Gafni","year":"2012","unstructured":"Gafni, J. et al. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J Neurosci. 32, 7454\u201365 (2012).","journal-title":"J Neurosci."},{"key":"25095_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1097-2765(02)00602-0","volume":"10","author":"A Lunkes","year":"2002","unstructured":"Lunkes, A. et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell. 10, 259\u201369 (2002).","journal-title":"Mol Cell."},{"key":"25095_CR35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s11095-005-9045-3","volume":"23","author":"JW Lee","year":"2006","unstructured":"Lee, J. W. et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 23, 312\u201328 (2006).","journal-title":"Pharm Res."},{"key":"25095_CR36","doi-asserted-by":"publisher","first-page":"297293","DOI":"10.1155\/2014\/297293","volume":"2014","author":"SY Chuang","year":"2014","unstructured":"Chuang, S. Y., Lin, C. H. & Fang, J. Y. Natural compounds and aging: between autophagy and inflammasome. Biomed Res Int. 2014, 297293 (2014).","journal-title":"Biomed Res Int."},{"key":"25095_CR37","doi-asserted-by":"crossref","unstructured":"Plaza-Zabala, A., Sierra-Torre, V. & Sierra, A. Autophagy and Microglia: Novel Partners in Neurodegeneration and Aging. Int J Mol Sci. 18 (2017).","DOI":"10.3390\/ijms18030598"},{"key":"25095_CR38","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1002\/mds.25578","volume":"28","author":"S Gluhm","year":"2013","unstructured":"Gluhm, S. et al. Usefulness of the Montreal Cognitive Assessment (MoCA) in Huntington\u2019s disease. Mov Disord. 28, 1744\u20137 (2013).","journal-title":"Mov Disord."},{"key":"25095_CR39","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.adolescence.2012.01.005","volume":"35","author":"DA Granger","year":"2012","unstructured":"Granger, D. A. et al. Focus on methodology: salivary bioscience and research on adolescence: an integrated perspective. J Adolesc. 35, 1081\u201395 (2012).","journal-title":"J Adolesc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25095-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25095-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25095-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T05:12:43Z","timestamp":1671599563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25095-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["25095"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-25095-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,9]]},"assertion":[{"value":"24 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7371"}}